Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis (NCT07039110)
The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)
🩺 Plain-English Summary (8th-Grade Level)
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice. Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide. Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Who can join: Review the eligibility criteria below.
Location: Dermatology Research Institute - Blackfoot Trail /ID# 276722 — Calgary, Alberta
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (81 Sites)
Showing the first 25 of 81 sites.
- Dermatology Research Institute - Blackfoot Trail /ID# 276722 — Calgary, Alberta
- Rejuvenation Dermatology - Edmonton Downtown /ID# 276688 — Edmonton, Alberta
- Winnipeg Clinic /ID# 276751 — Winnipeg, Manitoba
- Wiseman Dermatology Research /ID# 276847 — Winnipeg, Manitoba
- Cca Medical Research /ID# 276944 — Ajax, Ontario
- Quinte dermatology /ID# 277497 — Belleville, Ontario
- Dermatrials Research /ID# 276714 — Hamilton, Ontario
- Lovegrove Dermatology /ID# 276797 — London, Ontario
- Lynderm Research Inc /ID# 276755 — Markham, Ontario
- Rejuvenation Dermatology Clinic Oakville /ID# 277492 — Oakville, Ontario
- JRB Research inc. /ID# 277730 — Ottawa, Ontario
- Factor Dermatology /ID# 278610 — Ottawa, Ontario
- SKiN Centre for Dermatology /ID# 277594 — Peterborough, Ontario
- Eternal Springtime Dermatology /ID# 278598 — Thunder Bay, Ontario
- North York Research /ID# 276835 — Toronto, Ontario
- Toronto Dermatology Centre /ID# 276846 — Toronto, Ontario
- Centre for Medical and Surgical Dermatology /ID# 278775 — Whitby, Ontario
- Dre Angelique Gagne-Henley M.D. inc. /ID# 276687 — Saint-Jérôme, Quebec
- Fakultni Nemocnice U Sv. Anny V Brne /ID# 275799 — Brno, Brno-mesto
- Fakultni nemocnice Bulovka /ID# 275540 — Prague, Central Bohemia
- Dermafit Centrum /ID# 275897 — Pilsen, Plzeň Region
- Dermamedest /ID# 275898 — Prague, Praha 2
- Nemocnice Ceske Budejovice /ID# 275541 — České Budějovice,
- Fakultni nemocnice Kralovske Vinohrady /ID# 275800 — Prague,
- Chu de Dijon /ID# 279900 — Dijon, Bourgogne-Franche-Comté
📞 Contact the Study Coordinator
Phone: (844) 663-3742
Email: julieta.gonzalezblanco@abbvie.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis — Birmingham, Alabama
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Phoenix, Arizona
Explore by condition: All Plaque Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.